Loading
A phase 1/2 trial of ATX-898 run by Antares Therapeutics, Inc, now recruiting.
A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07767474 by Antares Therapeutics, Inc, with 343 participants planned, started 2026-08-31. Conditions recorded: Advanced Solid Tumors. Interventions recorded: ATX-898, ATX-898, ATX-898, ATX-898, ATX-898, ATX-898, fulvestrant, ribociclib, ATX-898, fulvestrant, ribociclib and ATX-898, fulvestrant, ribociclib.
Shares Antares Therapeutics and the tag pipeline.
Shares Antares Therapeutics and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/